Sharma et al. evaluated the safety and immunogenicity of a recombinant NY-ESO-1 protein vaccine, which was administered with GM-CSF and BCG as immunologic adjuvants, in a cohort of UC patients whose cancer cells expressed NY-ESO-1, a cancer/testis antigen [104]. The gene discussed is CSF2; the disease is cancer.